Skip to main
DCTH
DCTH logo

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc is poised for significant financial growth, with projected total revenues reaching $373 million by 2032, up from earlier estimates of $339 million, driven by the company's strategic expansion into the Medicaid Drug Rebate Program. The organization is consistently adding treatment centers and anticipates that positive outcomes from the CHOPIN trial and the National Drug Rebate Agreement will enhance drug adoption and improve profit margins. Additionally, Delcath has revised its revenue guidance for 2025, expecting product revenues of $95 million, a notable increase from previous forecasts, indicating strong growth potential even amidst anticipated pricing pressures.

Bears say

Delcath Systems Inc. has faced significant challenges, with preliminary third-quarter 2025 revenues reported at $20.5 million, representing a 15% quarter-over-quarter decline from $24.2 million and falling short of consensus estimates of $23.8 million. Management has notably lowered its full-year revenue guidance for FY2025 to a range of $83-$85 million from the previous $93-$96 million, which indicates a substantial downward revision in expectations. Additionally, the impact of discounts from HEPZATO's participation in the NDRA program and unexpected summer seasonality affecting patient scheduling suggests ongoing operational uncertainties that contribute to a negative outlook for the company's financial performance.

Delcath Systems (DCTH) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.